



Attorney Docket No.: 5843.200-US

RECEIVED

SEP 9 2002

TECH CENTER 1600/2900

PATENT

#10/par  
01-10-02

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Schüle et al.

Confirmation No: 1722

Serial No.: 09/576,778

Group Art Unit: 1652

Filed: May 23, 2000

Examiner: M. Rao

For: Family 9 Endo-Beta-1,4-Glucanases

**RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner for Patents  
Washington, DC 20231

Sir:

This paper is filed in response to the Office Action mailed September 26, 2001 that made restriction requirement between three groups.

Applicants hereby elect with traverse the invention of Group I (claims 1-5 and 22-24 drawn to endoglucanases). Applicants hereby reserve the right to file continuing applications directed to the nonelected subject matter.

The basis for traverse is that there would not be a serious burden on the examiner if Groups I and III were examined together.

Moreover, Applicants submit that claim 1 links inventions of Groups I and III. Therefore, upon allowance of the linking claim, the restriction requirement as to the linked inventions should be withdrawn and all claims within the linked inventions should be examined in the instant application.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this response or application.

Respectfully submitted,

Elias J. Lambiris, Reg. No. 33,728  
Novozymes North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123

Date: October 25, 2001



RECEIVED

JAN 9 2002

1652

TECH CENTER 1600/2900

PATENT

Attorney Docket No.: 5843.200-US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Schülein et al.

Confirmation No: 1722

Serial No.: 09/576,778

Group Art Unit: 1652

Filed: May 23, 2000

Examiner: M. Rao

For: Family 9 Endo-Beta-1,4-Glucanases

**CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)**

Commissioner for Patents  
Washington, DC 20231

Sir:

I hereby certify that the attached correspondence comprising:

1. Response to Restriction Requirement

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
Washington, DC 20231

on October 25, 2001.

Julie Tabarovsky  
(name of person mailing paper)

J. Tabarovsky  
(signature of person mailing paper)